Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z5LZ
|
||||
| Former ID |
DNC004251
|
||||
| Drug Name |
Tilmacoxib
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Colon polyps [ICD10:K63.5] | Discontinued in Phase 2 | [546604] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H19FN2O3S
|
||||
| Canonical SMILES |
CC1=NC(=C(O1)C2=CC(=C(C=C2)S(=O)(=O)N)F)C3CCCCC3
|
||||
| InChI |
1S/C16H19FN2O3S/c1-10-19-15(11-5-3-2-4-6-11)16(22-10)12-7-8-14(13(17)9-12)23(18,20)21/h7-9,11H,2-6H2,1H3,(H2,18,20,21)
|
||||
| InChIKey |
MIMJSJSRRDZIPW-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [526297] | |
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| NF-kappa B signaling pathway | |||||
| VEGF signaling pathway | |||||
| TNF signaling pathway | |||||
| Retrograde endocannabinoid signaling | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Oxytocin signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Leishmaniasis | |||||
| Pathways in cancer | |||||
| Chemical carcinogenesis | |||||
| MicroRNAs in cancer | |||||
| Small cell lung cancer | |||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| References | |||||
| Ref 526297 | J Med Chem. 2002 Mar 28;45(7):1511-7.4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.